What one share of Edesa Biotech holds
We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to acquire, develop and commercialize drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects.
Edesa Biotech’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.73 |
|---|---|
| Cash and investments | $1.07 |
| Book value | $0.91 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$2.93 | $0.00 | −$2.32 | — | $2.29 |
| 2024 | — | −$1.93 | — | — | — | $0.61 |
| 2025 | — | −$1.27 | — | — | — | $1.74 |
Common questions about Edesa Biotech
How much does one share of Edesa Biotech earn?
Over the last 12 months, Edesa Biotech lost $1.73 for each share.
Does Edesa Biotech pay a dividend?
Edesa Biotech didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Edesa Biotech’s book value per share?
Edesa Biotech’s book value is $0.91 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Edesa Biotech have?
Each share of Edesa Biotech has $1.07 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.